<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02068586</url>
  </required_header>
  <id_info>
    <org_study_id>13P.377</org_study_id>
    <secondary_id>2013-047</secondary_id>
    <nct_id>NCT02068586</nct_id>
  </id_info>
  <brief_title>Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma</brief_title>
  <official_title>A Randomized Phase ll Study of Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well sunitinib malate or valproic acid works in&#xD;
      preventing high-risk uveal (eye) melanoma from spreading to other parts of the body.&#xD;
      Sunitinib malate may stop the transmission of growth signals into tumor cells and prevents&#xD;
      these cells from growing. Valproic acid may change the expression of some genes in uveal&#xD;
      melanoma and suppress tumor growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      1) To assess the efficacy of adjuvant sunitinib malate or adjuvant valproic acid used for 6&#xD;
      months to improve overall survival (OS) at 2 years in patients with high-risk uveal melanoma.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
        1. To assess the efficacy of adjuvant sunitinib malate and adjuvant valproic acid used for&#xD;
           6 months in preventing the development of distal metastases (relapse-free survival, RFS)&#xD;
           in patients with high-risk uveal melanoma.&#xD;
&#xD;
        2. To confirm the safety and tolerability of 6 months of adjuvant sunitinib and adjuvant&#xD;
           valproic acid in patients with high-risk uveal melanoma.&#xD;
&#xD;
        3. To assess the quality of life during the adjuvant treatment.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      1) To determine whether blood myeloid-derived suppressor cells (MDSCs) concentration and&#xD;
      other inflammatory cytokines correlates with OS and RFS.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive sunitinib malate orally (PO) daily for 6 months in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients receive valproic acid PO daily for 6 months in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 2 years,&#xD;
      every 6 months for 3 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2014</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time of definitive treatment of the primary tumor until death from any cause, assessed at 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>Time of definitive treatment of the primary tumor until confirmed metastatic relapse or death from any cause, assessed at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as the proportion of patients able to complete 6 months of treatment, including those who underwent dose reduction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Ciliary Body and Choroid Melanoma, Medium/Large Size</condition>
  <condition>Ciliary Body and Choroid Melanoma, Small Size</condition>
  <condition>Iris Melanoma</condition>
  <condition>Stage I Intraocular Melanoma</condition>
  <condition>Stage IIA Intraocular Melanoma</condition>
  <condition>Stage IIB Intraocular Melanoma</condition>
  <condition>Stage IIIA Intraocular Melanoma</condition>
  <condition>Stage IIIB Intraocular Melanoma</condition>
  <condition>Stage IIIC Intraocular Melanoma</condition>
  <arm_group>
    <arm_group_label>Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sunitinib malate PO daily for 6 months in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive valproic acid PO daily for 6 months in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Sunitinib</arm_group_label>
    <other_name>Sunitinib malate</other_name>
    <other_name>Sutent</other_name>
    <other_name>SU11248</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Valproic acid</arm_group_label>
    <other_name>VPA</other_name>
    <other_name>Valproate</other_name>
    <other_name>Valproate sodium</other_name>
    <other_name>Depakote</other_name>
    <other_name>Epilim</other_name>
    <other_name>Valparin</other_name>
    <other_name>Valpro</other_name>
    <other_name>Stavzor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;= 18 years old.&#xD;
&#xD;
          2. Histologically-confirmed primary uveal melanoma.&#xD;
&#xD;
          3. Definitive local treatment for primary tumor, including surgical resection&#xD;
             (enucleation) or radiation therapy (radioactive plaque or external proton beam).&#xD;
&#xD;
          4. High risk for distal recurrence defined as any of the following conditions: A) -&#xD;
             Confirmed both monosomy 3 and 8q amplification; B) - Class II tumor.&#xD;
&#xD;
          5. Less than 6 months from the date that local treatment (surgical or radiation) of the&#xD;
             primary tumor was finalized.&#xD;
&#xD;
          6. Karnofsky performance status (PS) scores of 70 or greater.&#xD;
&#xD;
          7. If female, no pregnancy.&#xD;
&#xD;
          8. If of child-bearing potential (&lt; one year post-menopausal), must agree to practice an&#xD;
             effective method of avoiding pregnancy (including oral or implanted contraceptives,&#xD;
             intrauterine device, condom, diaphragm with spermicidal, cervical cap, abstinence or&#xD;
             sterile sex partner) from the time informed consent is signed (women only) or the time&#xD;
             of initiation of sunitinib (men only); both men and women must agree to continue using&#xD;
             such precautions while receiving sunitinib or valproic acid and for 30 days after the&#xD;
             final dose.&#xD;
&#xD;
          9. Adequate organ function that has been determined within 2 weeks prior to the study&#xD;
             entry, defined as:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1500/mm3, platelets ≥ 100,000/mm3, and&#xD;
                  hemoglobin ≥ 8 g/dl&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 times upper limit of normal range (ULN) or creatinine&#xD;
                  clearance ≥ 40 ml/min&#xD;
&#xD;
               -  Serum bilirubin &lt; 1.5 times ULN and serum albumin &gt; 2.0 g/dl&#xD;
&#xD;
               -  Adequate cardiac function (EF&gt; 50%) based on MUGA scan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other malignancy within 5 years, except curatively treated non-melanomatous skin&#xD;
             cancer, curatively treated carcinoma in situ of the uterine cervix, or early stage&#xD;
             (stage I or IIa) prostate cancer.&#xD;
&#xD;
          2. Metastatic uveal melanoma.&#xD;
&#xD;
          3. History of severe allergic reaction to sunitinib or valproic acid; inability to&#xD;
             receive sunitinib or valproic acid.&#xD;
&#xD;
          4. Previous treatment with sunitinib or valproic acid for uveal melanoma.&#xD;
&#xD;
          5. Active treatment with valproic acid for non-oncological conditions, if this cannot be&#xD;
             safely switched to an alternative agent.&#xD;
&#xD;
          6. Active epilepsy or convulsive conditions that require continuous use of&#xD;
             anticonvulsants.&#xD;
&#xD;
          7. Patients with known urea cycle disorders (i.e.: ornithine transcarbamylase&#xD;
             deficiency).&#xD;
&#xD;
          8. Severe cardiovascular disease within 6 months, including myocardial infarction,&#xD;
             severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic&#xD;
             congestive heart failure, cerebro-vascular accident or transient ischemic attack,&#xD;
             pulmonary embolism, life threatening arrhythmias, uncontrollable hypertension or QT&#xD;
             prolongation syndrome.&#xD;
&#xD;
          9. History of active liver disease (i.e. cirrhosis, viral or autoimmune hepatitis, etc.).&#xD;
&#xD;
         10. Pregnancy or unwillingness to stop breast-feeding.&#xD;
&#xD;
         11. Prior myelosuppressive chemotherapy or other investigational drug therapy within the&#xD;
             last 6 months prior to initiation of sunitinib or valproic acid.&#xD;
&#xD;
         12. Current evidence of hematemesis, melena or gross hematuria.&#xD;
&#xD;
         13. History or presence of any significant bleeding disorders.&#xD;
&#xD;
         14. Concurrent use of a strong CYP3A4 inhibitor or inducer (refer to Section 7). These&#xD;
             medications should be discontinued or switched to a different medication with a weaker&#xD;
             CYP3A4 interaction prior to enrollment into the study. If patients need to continue&#xD;
             the same medication(s), they are excluded from the study.&#xD;
&#xD;
         15. Chronic usage of aspirin greater than 81 mg/day.&#xD;
&#xD;
         16. Unable to render informed consent and to follow protocol requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takami Sato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takami Sato, MD</last_name>
    <phone>215-955-8874</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melanoma Research Group</last_name>
    <phone>215-955-9980</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takami Sato, MD</last_name>
      <phone>215-955-8874</phone>
    </contact>
    <contact_backup>
      <last_name>Melanoma Research Group</last_name>
    </contact_backup>
    <investigator>
      <last_name>Kendra Feeney, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Mastrangelo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carol Shields, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jerry Shields, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://www.JeffersonHospital.org</url>
    <description>Thomas Jefferson University Hospitals</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 19, 2014</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2014</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

